View Older Stories View More Recent Stories

Mar 7, 2017 04:17PM Portola Pharma (PTLA) Announces Betrixaban and AndexXa Presentations at ACC
Mar 7, 2017 04:05PM Portola Pharmaceuticals Announces Betrixaban and AndexXa™ (andexanet alfa) Presentations at ACC.17
Mar 1, 2017 08:00AM Portola Pharmaceuticals to Present at Two Upcoming Investor Conferences
Feb 28, 2017 04:05PM Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update
Feb 21, 2017 08:00AM Portola Pharmaceuticals to Announce Fourth Quarter and Year-End 2016 Financial Results and Host Conference Call on Tuesday, February 28
Feb 8, 2017 08:02AM Portola Pharma (PTLA) Informed by FDA No AdCom Planned for Betrixaban NDA
Feb 8, 2017 08:00AM FDA Informs Portola Pharmaceuticals at Mid-Cycle Review for Betrixaban That It Has Not Identified Issues that Require an Advisory Committee Meeting
Feb 3, 2017 08:03AM Portola Pharma (PTLA) Signs $150M Royalty Agreement with HealthCare Royalty Partners
Feb 3, 2017 08:00AM Portola Pharmaceuticals Signs $150 Million Royalty Agreement with HealthCare Royalty Partners for Development and Commercialization of Andexanet Alfa
Jan 3, 2017 08:00AM Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
Dec 23, 2016 02:13PM Portola Pharma (PTLA) Says FDA Accepts NDA with Priority Review for Betrixaban; EMA Validates MAA
Dec 23, 2016 02:12PM Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
Dec 19, 2016 08:04AM Portola Pharma (PTLA) Enters $50M Loan Agreement with Bristol-Myers Squibb (BMY) and Pfizer (PFE) to Continue AndexXa Development
Dec 19, 2016 08:00AM Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa)
Nov 28, 2016 08:00AM Portola Pharmaceuticals Announces AndexXa™ (andexanet alfa), Betrixaban and Cerdulatinib Data to be Presented at 2016 American Society of Hematology Annual Meeting and Exposition
Nov 14, 2016 04:24PM Portola Pharma (PTLA) Announces Strong Results from Three Betrixaban Phase 3 Substudies for VTE Prevention
Nov 14, 2016 04:15PM Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
Nov 7, 2016 04:05PM Portola Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
Nov 7, 2016 08:05AM Portola Pharma (PTLA) to Present Results from Betrixaban Phase 3 APEX Study at AHA Scientific Sessions
Nov 7, 2016 08:00AM Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data to be Presented at American Heart Association Scientific Sessions 2016
Nov 2, 2016 08:00AM Portola Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference
Nov 1, 2016 08:02AM Portola Pharma (PTLA) Enters Expanded AndexXa Development Agreement iwth Daiichi Sankyo
Nov 1, 2016 08:00AM Portola Pharmaceuticals Expands Clinical Collaboration Agreement with Daiichi Sankyo Worth Up to $25 Million to Develop AndexXa™ (andexanet alfa) in Germany
Oct 31, 2016 08:00AM Portola Pharmaceuticals to Announce Third Quarter 2016 Financial Results and Host Conference Call on Monday, November 7
Oct 25, 2016 08:08AM Portola Pharma (PTLA) Announces Submission of NDA for Betrixaban for Extended Duration Prophylaxis of VTE
Oct 25, 2016 08:00AM Portola Pharmaceuticals Submits New Drug Application to U.S. FDA for Betrixaban for Extended Duration Prophylaxis of Venous Thromboembolism in Acute Medically Ill Patients
Oct 13, 2016 06:07PM Portola Pharmaceuticals Supports “World Thrombosis Day” Campaign to Increase Awareness of Risks of Blood Clots
Sep 13, 2016 08:00AM Portola Pharmaceuticals Announces Upcoming Data Presentations on AndexXa™ (andexanet alfa) at Neurocritical Care Society 2016 Annual Meeting
Aug 30, 2016 06:07AM Portola Pharma (PTLA) Announces Positive Interim Data from AndexXa Phase 3b/4 in Acute Major Bleeding
Aug 30, 2016 04:01AM Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4™ Study of Factor Xa Inhibitor Antidote AndexXa™ (andexanet alfa) in Patients with Acute Major Bleeding
Aug 26, 2016 08:03AM Portola Pharma (PTLA) Announces Plans to Present Interim Phase 3b/4 ANNEXA-4 Data
Aug 26, 2016 08:00AM Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA™-4 Study of AndexXa™ (andexanet alfa) at European Society of Cardiology 2016 Congress
Aug 19, 2016 08:31AM Portola Pharma (PTLA) Says IndexXa MAA Accepted for Review in Europe
Aug 19, 2016 08:30AM Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa™ (andexanet alfa), a Factor Xa Inhibitor Antidote
Aug 18, 2016 06:16AM Portola Pharma (PTLA) Receives CRL from FDA for Andexanet Alfa
Aug 17, 2016 10:57PM Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa)
Aug 9, 2016 04:05PM Portola Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Aug 2, 2016 04:05PM Portola Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Tuesday, August 9
Jun 1, 2016 08:04AM Portola Pharma (PTLA) Commences Dosing in Cerdulatinib Phase 2a in r/r B-Cell and T-Cell Malignancies
Jun 1, 2016 08:00AM Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA
May 31, 2016 04:05PM Portola Pharmaceuticals to Present at Goldman Sachs 37th Annual Global Healthcare Conference
May 27, 2016 08:47AM Portola Pharma (PTLA) Announces Presentation, Publication of Full Phase 3 APEX Study Results in NEJM, ISTH SSC Meeting
May 27, 2016 08:45AM Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
May 23, 2016 08:07AM Portola Pharma (PTLA) Will Present Full Phase 3 APEX Study Data Set at Annual SSC Meeting
May 23, 2016 08:00AM Portola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and AndexXa™ (andexanet alfa) at International Society on Thrombosis and Haemostasis (ISTH) 2016 Scientific and Standardiz
May 5, 2016 04:05PM Portola Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update
Apr 28, 2016 08:00AM Portola Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Thursday, May 5
Apr 14, 2016 08:00AM Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016
Apr 6, 2016 08:05AM Portola Pharma (PTLA) Will Present Betrixaban Phase 3 APEX Data at 62nd Annual SSC Meeting
Apr 6, 2016 08:00AM Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis (ISTH) SSC Meeting 2016 on May 27, 2016
View More Recent Stories View Older Stories